EDESA BIOTECH INC (EDSA) Stock Price, Forecast & Analysis
USA - NASDAQ:EDSA - CA27966L3065 - Common Stock
EDSA Key Statistics, Chart & Performance
The current stock price of EDSA is 1.86 USD. In the past month the price decreased by -27.34%. In the past year, price decreased by -41.87%.
EDSA Latest News, Press Relases and Analysis
EDSA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.07 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 894.2 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.04 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About EDSA
Company Profile
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. The company is headquartered in Markham, Ontario and currently employs 16 full-time employees. The company went IPO on 2008-08-25. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Company Info
EDESA BIOTECH INC
100 Spy Crt
Markham ONTARIO L3R 5H6 CA
CEO: Pardeep Nijhawan
Employees: 16
Phone: 19054751234
EDESA BIOTECH INC / EDSA FAQ
What does EDSA do?
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. The company is headquartered in Markham, Ontario and currently employs 16 full-time employees. The company went IPO on 2008-08-25. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
What is the current price of EDSA stock?
The current stock price of EDSA is 1.86 USD. The price decreased by -0.53% in the last trading session.
Does EDSA stock pay dividends?
EDSA does not pay a dividend.
What is the ChartMill technical and fundamental rating of EDSA stock?
EDSA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of EDESA BIOTECH INC (EDSA)?
EDESA BIOTECH INC (EDSA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.32).
When does EDESA BIOTECH INC (EDSA) report earnings?
EDESA BIOTECH INC (EDSA) will report earnings on 2025-12-11, after the market close.
EDSA Technical Analysis
EDSA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EDSA. No worries on liquidiy or solvency for EDSA as it has an excellent financial health rating, but there are worries on the profitability.
EDSA Financial Highlights
Over the last trailing twelve months EDSA reported a non-GAAP Earnings per Share(EPS) of -1.32. The EPS increased by 41.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.98% | ||
| ROE | -41.89% | ||
| Debt/Equity | 0 |
EDSA Forecast & Estimates
8 analysts have analysed EDSA and the average price target is 10.54 USD. This implies a price increase of 466.67% is expected in the next year compared to the current price of 1.86.